The risk of skin cancer, malignant melanoma, now appears to be decreasing in Sweden—at least in those under 50, according to a new study.
2024
Experts Report Moderate Patient Adherence to Melanoma Screening and Surveillance Program
Researchers tailored screening and surveillance schedules to individual risk of patients.
EU and UK approve Microbiome Medicines for advanced melanoma and ulcerative colitis
Microbiotica has received the green light from EU and UK regulatory authorities to start phase 1b studies for its microbiome medicines in advanced melanoma and ulcerative colitis.
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.